Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:08:23.702Z.
Calculation as of: 2026-10-06T17:08:23.702Z.
Quote observation: 2026-10-06T17:05:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910
PE RATIO
N/A
Market Cap
$2.11B
PE Ratio
19.84
TTM Avg
21.19
3Y Avg
24.83
5Y Avg
28.15
Market Cap
$2.28B
PE Ratio
N/A
TTM Avg
6.84
3Y Avg
18.15
5Y Avg
20.42
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pharvaris N.V. (PHVS) | $2.15B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 19.84 | 21.19 | 24.83 | 28.15 |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.10B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.05B | N/A | 33.55 | 33.55 | 33.55 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | N/A | 34.42 | 34.42 | 34.42 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 7.63 | 7.63 | 7.63 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 28.27 | 33.84 | 41.30 | 55.21 |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | N/A | 6.84 | 18.15 | 20.42 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 6.84 | 15.39 | 40.25 | 40.25 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
